COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk We conducted a two-round modified Delphi survey. Participants were patients (or their carers) who had ...
Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
Bottom Line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to ...
New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...
ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...
In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses the toxicity of drugs such as Plaquenil.
Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback